Skip to content

Homocysteine, inflammatory factors, safety study of scutellarin for injection in patients with acute cerebral infarction - a single center, randomized, open label clinical trial

Homocysteine, inflammatory factors, safety study of scutellarin for injection in patients with acute cerebral infarction - a single center, randomized, open label clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100005042
Enrollment
Unknown
Registered
2021-07-11
Start date
2021-07-19
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute cerebral infarction

Interventions

Sponsors

Yunnan Third People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for acute ischemic stroke; 2. Patients with mild to moderate elevation of homocysteine; 3. The time from onset of stroke symptoms or signs to treatment is <=72 hours; 4. The modified Rankin Scale (mRS) score of the first onset or before onset is between 0 and 1; 5.4<=NIHSS score<=15 points; 6. Age 18-80 years old (including 18 and 80 years old), gender is not limited; 7. Voluntarily participate and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Due to encephalitis, brain tumor, brain abscess and diseases that cause similar symptoms; 2. Transient ischemic attack; 3. Patients who are using traditional Chinese medicine injections for promoting blood circulation and removing blood stasis (including Danshen preparations, Ginkgo preparations, and Xuesaitong preparations); 4. Patients who are using folic acid, vitamin B6 or vitamin B12; 5. Have bleeding disorders or bleeding tendency; 6. Patients treated with vascular opening (such as thrombolysis, arterial thrombectomy, ultra-early thrombus aspiration and stenting, etc.) after the onset; 7. Patients with severe disturbance of consciousness (NIHSS 1a consciousness level item >= 2 points); 8) Those with other diseases that affect the function of limb movement, such as claudication, osteoarthritis (active stage), rheumatoid arthritis (active stage), gouty arthritis, etc. The limb movement dysfunction may affect the nerve or functional examination By; 9. Combined with severe cardiovascular disease (New York Heart Function Class (NYHA) grade III and above, unstable angina pectoris, myocardial infarction within 6 months before administration, uncontrolled arrhythmia, etc.); 10. Severe liver and kidney dysfunction; 11. Patients with tumors and other serious diseases of the system; 12. Those who are known to be allergic to the components of the test drug and have allergic constitution; 13. Women who are pregnant, planning to become pregnant or breastfeeding; Patients who participated in other clinical trials within 14.3 months.

Design outcomes

Primary

MeasureTime frame
Homocysteine level;

Countries

China

Contacts

Public ContactZhang Ling

Yunnan Third People's Hospital

542374859@qq.com+86 13888049715

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026